Microvilli length predicts clinical response to ustekinumab in Crohn's patients from the UNITI-2 trial

(1) University of Cincinnati College of Medicine,Cincinnati,United States

(2) Janssen Research & Development,Spring House,United States

(3) Washington University School of Medicine,St. Louis,United States

(4) Harvard Medical School,Boston,United States

(5) Washington University Medical School,St. Louis,United States



This item was part of the Late breaking abstracts: IBD Highlights session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019